Pemetrexed

The following materials were commercially obtained: Gefitinib (Biaffin, Kassel, Germany); Erlotinib (kindly provided from Roche Diagnostics, Mannheim, Germany); Cisplatin (Wako Pure Chemical Industries, Osaka, Japan); Pemetrexed (Wako Pure Chemical Industries); TGF-β1 (PeproTech, Rocky Hill, USA).
Antibodies were obtained from the following sources: p22^phox [E-11] (Santa Cruz Biotechnology, Santa Cruz, CA, USA); HIF-1α [h1alpha67] (Abcam, Cambridge, UK), E-cadherin [4A2C7] (Thermo Fisher Scientific, Rockford, USA), Vimentin [V9] (Acris, San Diego, USA), β-actin [AC-15] (Sigma-Aldrich, St. Louis, MO, USA).

Methotrexate, leucovorin (calcium folinate), and CEP1347 (synthesized product code FE29092) were purchased from Tokyo Chemical Industry co., LTD (Tokyo, Japan). Pemetrexed was purchased from FUJIFILM Wako Chemicals (Osaka, Japan). CEP1347 was dissolved in DMSO to prepare a 1 mM stock solution. Methotrexate and Pemetrexed were dissolved in 1 M NaOH or DDW to prepare 100 mM and 10 mM stock solutions for in vitro study. Methotrexate and leucovorin were dissolved in 0.1 N NaOH or DDW to prepare 20 mg/mL stock solutions for the mouse study. An antibody against SOX2 (MAB2018) was purchased from R&D Systems Inc. (Minneapolis, MN, USA). Antibodies against cleaved PARP (#9541), cleaved caspase 3 (#9661), GFAP (#3670), and GAPDH (#5174) were purchased from Cell Signaling Technology Inc. (Beverly, MA, USA). Anti-RFC-1 (sc-390948) and anti-FR (sc-515521) were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). An antibody against DHFR (NBP1-47727) was purchased from Novus Biologicals, LLC (Centennial, CO, USA).